Results from a new study published in the American Heart Association’s Hypertension showed that the GLP-1, tirzepatide, reduced 24-hour systolic BP, both at night and in the daytime compared with placebo.

CDC stated that the United States is seeing the highest incidence of syphilis since 1950. In its new report, the agency maps out an astonishing comeback for a disease that had previously reached near-eradication status.

Patients paid less money out of pocket for naloxone from 2018 through 2022, according to a new analysis published in JAMA. The research, which was based on data from the IQVIA Longitudinal Prescription database, revealed that the mean out-of-pocket cost per prescription declined from $22.51 in 2018 to $10.02 in 2022.

Incorporating an additional 6 years of data, researchers updated a previously published analysis of gabapentinoid use among Americans.

A global increase in severe antimicrobial-resistant fungal infections of the skin—partly due to inappropriate use of topical antifungals and antifungal-corticosteroid combinations—has found its way to the United States.